BMC Cancer (Aug 2020)

Long term outcome of anastomotic leakage in patients undergoing low anterior resection for rectal cancer

  • Alice Artus,
  • Nicolas Tabchouri,
  • Othman Iskander,
  • Nicolas Michot,
  • Olivier Muller,
  • Urs Giger-Pabst,
  • Pascal Bourlier,
  • Céline Bourbao-Tournois,
  • Aurore Kraemer-Bucur,
  • Thierry Lecomte,
  • Ephrem Salamé,
  • Mehdi Ouaissi

DOI
https://doi.org/10.1186/s12885-020-07109-4
Journal volume & issue
Vol. 20, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Background The influence of anastomotic leakage (AL) on local recurrence rates and survival in rectal cancer remains controversial. The aim of this study was to analyze the effect of asymptomatic anastomotic leakage (AAL) and symptomatic anastomotic leakage (SAL) on short- and long-term outcome after curative rectal cancer resection. Methods All patients who underwent surgical resection of non-metastatic rectal cancer with curative intent from January 2005 to December 2017 were retrospectively analyzed. Short-term morbidity, long-term functional and oncological outcomes were compared between patients with SAL, AAL and without AL (WAL). Results Overall, 200 patients were included and AL was observed in 39 (19.5%) patients (10 AAL and 29 SAL) with a median follow-up of 38.5 months. Rectal cancer location and preoperative neoadjuvant treatment was similar between the three groups. Postoperative 30-day mortality rate was nil. The permanent stoma rate was higher in patients with SAL or AAL compared to WAL patients (44.8 and 30% vs 9.3%, p < 0.001). The mean wexner continence grading scale was significantly different between AAL (11,4 ± 3,8), SAL (10,3 ± 0,6) and WAL (6,4 ± 4,7) groups (p = 0.049). The 3 and 5-year overall and disease-free survival rates were similar between the 3 groups (86.6% /84% vs 100%/100% vs 76%/70 and 82.9%/77% vs 100%/100% vs 94.7%/88.3% for patients with SAL, AAL, and WAL, p = 0.480 and p = 0.527). Conclusion The permanent stoma rate was significant higher in patients with SAL or AAL compared to WAL patients. AL did not impair long-term oncological outcome.

Keywords